Puberty blockers trial paused after MHRA raises safety concerns.

A pivotal clinical trial designed to meticulously assess the intricate risks and potential benefits of puberty-blocking drugs for children experiencing gender dysphoria has been abruptly paused. This significant halt comes in the wake of serious safety concerns formally raised by the Medicines and Healthcare Products Regulatory Agency (MHRA), the UK’s stringent medicines watchdog. The MHRA is scheduled to convene crucial discussions with researchers from King’s College London, who are spearheading this complex trial, next week. These vital talks are intended to address the specific safety concerns that have prompted this pause, according to an official statement from the government.

The trial, known as "Pathways," was initially announced in November, having secured approval from both the MHRA and the Health Research Authority. It was projected to enroll over 220 children, with an age range spanning approximately 11 to 15 years old. The primary objective of the Pathways trial was to delve into the multifaceted impacts of puberty-suppressing hormones (PSH) on the physical, social, and emotional well-being of young individuals who are distressed by their gender identity and are currently accessing specialist gender services. However, the MHRA’s intervention casts a shadow over these plans, highlighting a need for enhanced safeguarding measures.

A spokesperson for the MHRA emphasized that the "safety and wellbeing" of the participants, who have yet to be recruited, remains "paramount." This statement underscores the agency’s commitment to ensuring that the welfare of vulnerable young people is the foremost consideration in any research involving medical interventions. It is pertinent to note that the use of puberty blockers for individuals under 18 who are questioning their gender identity was officially banned in the UK in 2024, following recommendations from a comprehensive review. The drugs, also referred to as puberty suppressing hormones (PSH), function by temporarily delaying or halting the onset of puberty.

The MHRA’s specific concerns appear to center on several key areas. The agency has suggested an increase in the minimum age limit for trial participants to 14 years old. Furthermore, the MHRA has called for more in-depth monitoring of participants’ bone density, a critical aspect given the potential long-term effects of hormonal interventions. A more rigorous and robust consent process for participants has also been recommended, reflecting the sensitive nature of the treatment and the need for fully informed agreement.

In a formal letter published on the government website, the MHRA articulated its concerns regarding the current age eligibility criteria for the trial. The letter states, "Since potentially significant and, as yet, unquantified risk of long-term biological harms is present to participants and biological safety has not been definitively demonstrated in this proposed cohort, at the very least, there should be a graded/stepwise approach starting with those aged 14 as the lower limit of eligibility." This explicit statement highlights the MHRA’s assessment of potential, yet unquantified, long-term biological risks associated with the treatment in this specific cohort.

In a separate statement issued on Friday evening, an MHRA spokesperson reiterated that the agency’s involvement is part of a "usual process" where clinical trials are "kept continuously under review." This ongoing scientific dialogue with trial sponsors is standard practice. "We have raised some concerns related to the wellbeing of participants and scientific dialogue will now follow with the trial sponsor," the spokesperson added, confirming the active engagement between the regulatory body and the research team.

The Department of Health & Social Care (DHSC) has affirmed its stance, stating that participants will not be recruited for the trial until all issues raised by the MHRA have been resolved through discussions with the trial clinicians. A DHSC spokesperson articulated the government’s unwavering commitment to safeguarding the children and young people involved, emphasizing that any decision regarding the trial will be "led by the clinical evidence." The spokesperson further asserted that the trial "would only be allowed to go ahead if the expert scientific and clinical evidence and advice conclude it is both safe and necessary," reinforcing the stringent criteria for its progression.

A spokesperson for King’s College London echoed the sentiment of prioritizing the well-being and health of young people experiencing gender incongruence and their families. The institution acknowledged the importance of "rigour and ongoing scientific discussion" in the context of clinical trials, particularly one as complex and sensitive as the Pathways trial. This indicates a willingness to engage constructively with the MHRA’s concerns.

However, the trial has not been without its critics. Several medical professionals have publicly questioned the necessity of the trial, given the current evidence base and the existing ban on puberty blockers for under-18s. Campaigners have also initiated legal action against the MHRA, the government, and other entities involved in the trial, arguing that it is unethical and that children may not be able to provide fully informed consent to treatments that could impact their future fertility.

The 2024 review conducted by Dr. Hilary Cass provided a critical assessment of gender medicine in the UK, finding that it had been operating on "shaky foundations" regarding the evidence supporting treatment protocols. The ban on puberty blockers for under-18s was a direct consequence of the concerns raised in this review regarding their safety and efficacy.

Journalist Hannah Barnes, the investigations editor at The New Statesman and author of "Time to Think," a book examining the UK’s gender identity service, described the MHRA’s letter as "pretty significant." Barnes suggested that, upon close examination, the letter "pretty much throws out the current trial design." She further commented that if doctors and clinicians wish to reconfigure the trial, they will need to do so in a manner that is "safer" and provides "better monitoring for these vulnerable children." Barnes concluded her assessment by stating, "I think the trial in its current design is totally dead," implying that a substantial redesign would be required for it to proceed. The pause in the Pathways trial signifies a critical juncture in the ongoing debate and scientific inquiry surrounding gender-affirming care for young people in the UK, emphasizing the paramount importance of safety, rigorous evidence, and comprehensive ethical considerations.